This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Allscripts' (MDRX) Q3 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.
AllScripts Healthcare (MDRX) Q3 Earnings Surpass Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 50.00% and -1.91%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate AllScripts Healthcare (MDRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and various innovation milestones.
Allscripts' (MDRX) New AI-Based Offering to Improve Patient Care
by Zacks Equity Research
Allscripts' (MDRX) latest AI-based scheduling application is expected to provide improved patient care as well as increase operational efficiencies of the healthcare system.
Cerner's (CERN) Latest Offering to Improve RCM Portfolio
by Zacks Equity Research
Cerner's (CERN) latest offering is likely to streamline and automate revenue cycle via interoperability and enhanced usability.
Allscripts (MDRX), CareMetx Tie Up for Better Patient Care
by Zacks Equity Research
Allscripts' (MDRX) Veradigm enters collaboration with CareMetx to streamline specialty medication management for medical clinics and practices across the nation.
Syneos Health's (SYNH) New Pact Boosts Tech-Driven Solutions
by Zacks Equity Research
Syneos Health's (SYNH) recent acquisition boosts the company's ability to deliver strategic insights and technology-enabled solutions that address the customers' most complex data challenges.
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Allscripts' (MDRX) Shares Up Following Q2 Earnings Beat
by Zacks Equity Research
Allscripts' (MDRX) robust Q2 results demonstrate its strength in Client services segment.
AllScripts Healthcare (MDRX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 27.78% and 0.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AllScripts Healthcare (MDRX) to Report Q2 Results: What to Know Ahead of the Release
by Zacks Equity Research
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MedTech Thrives on Healthcare IT in 2021: 4 Stocks to Focus on
by Debanjana Dey
Health IT stocks like HealthEquity (HQY), Veeva Systems (VEEV), Tabula Rasa (TRHC) and Allscripts (MDRX) are expected to continue their run over the next few months.
3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19
by Riya Anand
Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.
The Zacks Analyst Blog Highlights: Boyd Gaming, International Game Technology, Allscripts Healthcare, Zoom Video and Thryv Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boyd Gaming, International Game Technology, Allscripts Healthcare, Zoom Video and Thryv Holdings
Invest in 3 Top-Performing Sectors for Gains in 2H21
by Urmimala Biswas
Amid the current market incongruity, investors should definitely invest in the best- performing sectors for secure gains ahead.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.
Allscripts' (MDRX) Unit Inks Deal to Boost Clinical Research
by Zacks Equity Research
Allscripts' (MDRX) unit, Veradigm, enters into a strategic partnership with PRA Health (PRAH) to expand patients' access to clinical research.
Digital Health Momentum is Here to Stay: 3 MedTech Stocks in Focus
by Trina Mukherjee
Here we look at three stocks, MDRX, CERN and RMD, that investors can keep a watch on the back of their robust digital health prospects.
3 Stocks With Telehealth Offerings for Post-Pandemic Gains
by Riya Anand
Stocks like CVS Health (CVS), Walgreens Boots Alliance (WBA) and Allscripts (MDRX) are expected to continue to grow post-pandemic on a series of remote health care product and service launches.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.
Allscripts (MDRX), Lash Group Team Up for Better Patient Care
by Zacks Equity Research
Allscripts' (MDRX) Veradigm enters collaboration to streamline specialty medication management for medical clinics and practices across the nation.
Allscripts (MDRX) Inches Up 0.3% on Earnings Beat in Q1
by Zacks Equity Research
Allscripts (MDRX) witnesses a year- over- year surge in earnings during Q1.
AllScripts Healthcare (MDRX) Tops Q1 Earnings Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 26.67% and -0.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?